ArticleThe Journal of international medical research2022
The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.
Shujiao He, Minjie Zhang, Jieying Li, Weiqiang Zhao, Li Yu, Ying Han, Yanbin Pang
Open access · goldAbstract readCase Reports
In one paragraphArticle in The Journal of international medical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors at 3 institutions in 1 country.
Shujiao HeDepartment of Haematology-Oncology, International Cancer Centre, Shenzhen Key Laboratory, Haematology Institution of Shenzhen University, Shenzhen University General Hospital, Shenzhen University Health Science Centre, Shenzhen, China.
Minjie ZhangDepartment of Obstetrics, Shenzhen University General Hospital, Shenzhen, China.
Jieying LiDepartment of Haematology-Oncology, International Cancer Centre, Shenzhen Key Laboratory, Haematology Institution of Shenzhen University, Shenzhen University General Hospital, Shenzhen University Health Science Centre, Shenzhen, China.
Weiqiang ZhaoDepartment of Haematology-Oncology, International Cancer Centre, Shenzhen Key Laboratory, Haematology Institution of Shenzhen University, Shenzhen University General Hospital, Shenzhen University Health Science Centre, Shenzhen, China.
Li YuDepartment of Haematology-Oncology, International Cancer Centre, Shenzhen Key Laboratory, Haematology Institution of Shenzhen University, Shenzhen University General Hospital, Shenzhen University Health Science Centre, Shenzhen, China.
Yanbin PangDepartment of Haematology-Oncology, International Cancer Centre, Shenzhen Key Laboratory, Haematology Institution of Shenzhen University, Shenzhen University General Hospital, Shenzhen University Health Science Centre, Shenzhen, China.ORCID https://orcid.org/0000-0002-5866-9706 Shenzhen University Health Science Center · CNAffiliated Hospital of Hebei University · CNShenzhen University · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
A Y842D mutation within the activation loop of fms-like tyrosine kinase 3 (FLT3) has been shown to confer strong resistance to sorafenib
Indexed as
fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteHumansMutationProtein Kinase InhibitorsStaurosporineFLT3 protein, humanfms-Like Tyrosine Kinase 3midostaurinProtein Kinase InhibitorsStaurosporineactivation mutationacute myeloid leukaemiacase reportdifferentiation syndromeFMS-like tyrosine kinase 3midostaurin
Identifiers
PMID35549749
PMCPMC9251825
OpenAlexW4280542007
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390